x
Loading
+ -

Economic impact & innovation

"Science Start-Up of the Year 2018" Awards in Berlin
Simon Ittig (in the middle), CEO of T3 Pharma, a University of Basel start-up, at the "Science Start-Up of the Year 2018" Awards in Berlin. Right: Christian Elias Schneider, Head of Innovation and Entrepreneurship at the University of Basel. Image: Falling Walls

The new innovation activities at the University of Basel aim to help the public at large reap even greater benefit from knowledge generated at the university and to boost the region’s economy. In 2018, the main focus was on providing excellent support to start-ups and spin-offs.

Goals
Actions
Responsible
Goals

Measuring the impact of the Innovation & Corporate Relations Office

Actions
  • Establishing annual data collection process to measure investments in University of Basel start-ups and spin-offs
  • Recording key figures on the number of jobs created annually by the Innovation & Corporate Relations Office
  • Recording key figures on priority patent applications, approved priority patents, licenses/options, new licensed products introduced to the market, spin-offs, start-ups, start-ups operating in the university’s innovation spaces
Responsible

Innovation & Corporate Relations

Goals

Monitoring and strengthening the innovator community at the University of Basel

Actions
  • Recording the number of active community members per year (raising awareness, start-up projects, start-ups, supporters)
  • Recording the number of workshops and projects with companies
Responsible

Innovation & Corporate Relations

Highlights

T3 Pharma, a University of Basel start-up, was named «2018 Science Start-Up of the Year» at the highly touted Falling Walls Conference in Berlin. The biotech company, which specializes in immuno-oncology, received an award for its groundbreaking approach to bacterial cancer therapy. T2 Pharma stimulates the immune system with modified bacteria, which release specific human proteins directly in the cells found in the micro-region around the tumor. T3 Pharmaceuticals is a start-up that was founded at the University of Basel in May 2015.

Technology transfer in 2018

Invention disclosures

34

Priority patent applications

19

Licenses / options

23

New licensed products introduced to the market

4

Spin-Offs founded

1

Start-ups & spin-offs in the innovation spaces

8

Virtual Reality Simulation at the "Innovation Day" of the University of Basel in Allschwil.
Virtual Reality Simulation at the "Innovation Day" of the University of Basel in Allschwil.

The process for applying research findings or ideas is quantified in terms of patent applications, licenses and the number of spin-offs monitored by the organization Unitectra. Spin-offs can rent the university’s innovation spaces and benefit from favorable terms and the support of the community. When implementing technology and ideas for society, the collaboration with industry partners plays a key role, particularly in the Basel region. Economic sustainability and academic freedom are ensured through close monitoring by the Innovation Office. In 2018, 20 workshops were held together with companies, and two specific projects were launched with companies.

To top